Company / Operating Income
ArriVent BioPharma, Inc. Operating Income History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$94.3M
FY2024
5-year range
-$94.3M / -$74.6M
FY2023-FY2024
Trend
-26.4%
vs FY2023
Sector context
#90 of 204
Health Care
What the data says
At -$94M, ArriVent BioPharma, Inc.'s operating income ranks #90 of 204 in the Health Care sector.
Based on SEC 10-K filings.
-$94M in FY2024.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#90 of 204 in Health CareTop 44% of 204This company -$94.3M Sector average $107.7M
▼
-187.6% below sector average
Key checks
Key Insights
- In FY2024, operating income decreased 26.4% year-over-year.
- Ranks #90 out of 204 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.74 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$94.3M | -26.4% |
| FY2023 | -$74.6M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026